Search - tctmd.com

Displaying 181 - 200 of 626

Sort: Relevancy | Date

Presentation TCT 2018

SOLVE-TAVI: Summary and Clinical Implications

Presenter: Andreas Baumbach, Stephan Windecker, Holger Thiele

September 23, 2018

Presentation TCT 2018

Non-Inferiority Trials Gone Wrong: Examples From the Recent Literature

Presenter: Peter Juni, Robert W. Yeh, David J. Cohen

September 23, 2018

Presentation TCT 2018

Transcatheter Tricuspid Valve Therapies: Challenging Technologies and Clinical Trial Pathways

Presenter: Jaime Raben, Josep Rodés-Cabau

September 23, 2018

Presentation TCT 2018

SORT OUT IX: Summary and Clinical Implications

Presenter: Andreas Baumbach, Stephan Windecker, Lisette Okkels Jensen

September 23, 2018

Presentation TCT 2018

Most Frequent Errors I See in the Analysis and Interpretation of Trials

Presenter: Peter Juni, Robert W. Yeh

September 23, 2018

Presentation TCT 2018

How to Make Trials Larger, Simpler and Less Expensive

Presenter: Peter Juni, Robert W. Yeh, Matthew T. Roe

September 23, 2018

Presentation TCT 2018

LEADERS FREE II: Summary and Clinical Implications

Presenter: Andreas Baumbach, Stephan Windecker, Mitchell W. Krucoff

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, William F. Fearon

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Bernard J. Gersh

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

Presenter: Ajay J. Kirtane, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Rasha Al-Lamee

September 23, 2018

News Conference News TCT 2018

SOLVE-TAVI: TAVR Equally Safe With Balloon-, Self-Expanding Valves and General, Local Anesthesia

Yael L. Maxwell

September 23, 2018

Presentation TCT 2018

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

Presenter: E. Magnus Ohman, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

What Are the Lasting Clinical Implications Of the ORBITA Trial?

Presenter: Anibal A. Damonte, Diego D Grinfeld, Alfredo E. Rodriguez, John A. Ambrose

September 23, 2018

Presentation TCT 2018

Patient Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Debbe McCall

September 23, 2018

News Conference News TCT 2018

Denervation Has Possible Benefit for Pulmonary Hypertension Related to Left Heart Failure

Todd Neale

September 23, 2018

News Daily News TCT 2018

High Mortality but Durable Results With Valve-in-Valve TAVR

Michael O'Riordan

September 23, 2018

Presentation TCT 2018

FDA Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Hiren Mistry

September 23, 2018

Presentation TCT 2018

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Presenter: E. Magnus Ohman, Stuart J. Pocock, David J. Maron

September 23, 2018

Presentation TCT 2018

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Presenter: E. Magnus Ohman, Stuart J. Pocock, Sanjay Kaul

September 23, 2018

Advertisement

SOLVE-TAVI: Summary and Clinical Implications

Non-Inferiority Trials Gone Wrong: Examples From the Recent Literature

Transcatheter Tricuspid Valve Therapies: Challenging Technologies and Clinical Trial Pathways

SORT OUT IX: Summary and Clinical Implications

Most Frequent Errors I See in the Analysis and Interpretation of Trials

How to Make Trials Larger, Simpler and Less Expensive

LEADERS FREE II: Summary and Clinical Implications

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

SOLVE-TAVI: TAVR Equally Safe With Balloon-, Self-Expanding Valves and General, Local Anesthesia

All-Cause Mortality and Interpretation of Secondary Endpoints: The VEST and ODYSSEY Examples

What Are the Lasting Clinical Implications Of the ORBITA Trial?

Patient Perspectives on Sham-Controlled Trials

Denervation Has Possible Benefit for Pulmonary Hypertension Related to Left Heart Failure

High Mortality but Durable Results With Valve-in-Valve TAVR

FDA Perspectives on Sham-Controlled Trials

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Composite Endpoints: When Are They Valid and When Should They Be Discarded

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content